Virtual Library

Start Your Search

Alessandro Russo



Author of

  • +

    P1.04 - Immunooncology (Not CME Accredited Session) (ID 936)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.04-28 - Baseline Markers of Inflammation and Outcome with Nivolumab in Pretreated Non Small Cell Lung Cancers: A Retrospective Study. (ID 13858)

      16:45 - 18:00  |  Presenting Author(s): Alessandro Russo

      • Abstract
      • Slides

      Background

      Nivolumab is a novel therapeutic option in pre-treated Non Small Cell Lung Cancer(NSCLC), independently of tumor histology and PD-L1 status. However, predictive biomarkers are lacking. We aimed to evaluate whether there is a correlation between some baseline markers of inflammation and the outcome of patients (pts) treated with Nivolumab.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      All consecutive NSCLC pts treated with Nivolumab between Aug. 2015-Dec. 2017 at our Institution were analyzed. Baseline characteristics were collected and correlated with the outcome. Derived neutrophil-to-lymphocyte (dNLR) ratio was calculated as: neutrophil count/white blood count – neutrophil count. Platelet-to-lymphocyte (PLR) ratio was defined as platelet count/lymphocyte count. Overall survival (OS) was defined as time from Nivolumab start to death and Progression Free Survival (PFS) as time from Nivolumab start to progression disease or death for any cause. OS and PFS survival were estimated using the Kaplan–Meier method. Survival curves were compared using the log-rank test.

      4c3880bb027f159e801041b1021e88e8 Result

      We included 45 consecutive NSCLC pts treated with Nivolumab. Baseline characteristics were as follows: median age 69 years (range 46-78), sex male 78%, female 12%, squamous histology in 51% and non-squamous in 49%. After a median follow-up of 16 months (mos), median PFS was 4.0 mos (CI 95%, 2-8) and median OS was 9.0 mos (CI 95%, 4-15). High neutrophil count (≥7500/mmc) and high lymphocyte count (≥1000/mmc) were associated with a shorter PFS (p=0.05 and p=0.01, respectively) and OS (p=0.373 and p<0.001, respectively), as well as low albumin levels (<3 g/dl) (p=0.05 for both PFS and OS). Moreover, a high dNLR (≥3), high PLR (≥160) and high LDH levels (> Upper Limit Normal) correlated with a numerically longer PFS and OS, although these differences were not statistically significant.

      8eea62084ca7e541d918e823422bd82e Conclusion

      Baseline markers of inflammation correlate with inferior outcome with Nivolumab in unselected, pretreated, NSCLCs. The relative easy estimation of these parameters may be used with other predictive biomarkers in the treatment selection of pts candidate for immunotherapy.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.